Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12
The DOI matches its Crossref record.
Abstract
The cellular and molecular mechanisms of IL-12-mediated anti-tumor activity have been examined. BALB/c mice bearing established s.c. RENCA or CT26 tumors that were treated daily with IL-12 showed essentially complete tumor regression while tumors in untreated animals grew progressively. Examination of inflammatory gene expression in tumor tissue from treated vs untreated mice revealed the selective expression of IFN-γ and the IFN-γ-inducible CXC chemokine IP-10. Immunohistologic analysis demonstrated that tumors from treated mice were heavily infiltrated with CD8+ T cells and Mac-1+ mononuclear cells. Tumor regression in IL-12-treated mice was associated with expression of the lytic effector molecules perforin and granzyme B. These findings support the hypothesis that the anti-tumor function of IL-12 treatment depends upon the induced expression of IFN-γ by T cells and/or NK cells, the amplification of the immune response mediated by IFN-γ-induced expression of chemoattractant cytokines, and the IL-12-dependent potentiation of the cytolytic effector function of recruited CD8+ T cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Interleukin-12: A Cytokine at the Interface of Inflammation and Immunity
Trinchieri, G. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60387-9 · Cited by 760
Neville, L. F., Mathiak, G., & Bagasra, O. (1997) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(97)00015-4 · Cited by 350
Immune defects observed in patients with primary malignant brain tumors
Dix, A. R., Brooks, W. H., Roszman, T. L., & Morford, L. A. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00203-9 · Cited by 323
Boggio, K., Nicoletti, G., Di Carlo, E., Cavallo, F., Landuzzi, L., Melani, C., Giovarelli, M., Rossi, I., Nanni, P., De Giovanni, C., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.3.589 · Cited by 302
The Anti-Tumor Activity of IL-12: Mechanisms of Innate Immunity That Are Model and Dose Dependent
Smyth, M. J., Taniguchi, M., & Street, S. E. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.5.2665 · Cited by 301
Tannenbaum, C. S., Tubbs, R., Armstrong, D., Finke, J. H., Bukowski, R. M., & Hamilton, T. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.2.927 · Cited by 294
Self-citationIL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production
Jaime-Ramirez, A. C., Mundy-Bosse, B. L., Kondadasula, S., Jones, N. B., Roda, J. M., Mani, A., Parihar, R., Karpa, V., Papenfuss, T. L., LaPerle, K. M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000328 · Cited by 100
IL-12 Regulates an Endothelial Cell-Lymphocyte Network: Effect on Metalloproteinase-9 Production
Mitola, S., Strasly, M., Prato, M., Ghia, P., & Bussolino, F. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.7.3725 · Cited by 58
Charbonneau, B., Maurer, M. J., Ansell, S. M., Slager, S. L., Fredericksen, Z. S., Ziesmer, S. C., Macon, W. R., Habermann, T. M., Witzig, T. E., Link, B. K., et al. (2012) · Cytokine · doi:10.1016/j.cyto.2012.08.028 · Cited by 55
“Because IL-12 induces IFN-γ expression, which in turn increases expression of both IP-10 and MIG [43], it is likely that these cytokines really represent activation of the same pathway [43,44].”
BackgroundPizzoferrato, E., Chu, N. R., Hawley, T. S., Lieu, F. H. L., Barber, B. H., Hawley, R. G., Watts, T. H., & Berinstein, N. L. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.18-2217 · Cited by 28
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells
Parihar, R., Dierksheide, J., Hu, Y., & Carson, W. E. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215950 · Cited by 23
Metadata
- Authors
- Tannenbaum, C. S., Wicker, N., Armstrong, D., Tubbs, R., Finke, J., Bukowski, R. M., & Hamilton, T. A.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1996-01
- Volume
- 156
- Issue
- 2
- Pages
- 693-699
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1485835599
- Cited by
- 155
- References
- 0
- FWCI
- 7.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.